217 related articles for article (PubMed ID: 19461405)
1. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.
Bisagni G; Rossi G; Cavazza A; Sartori G; Gardini G; Boni C
J Thorac Oncol; 2009 Jun; 4(6):773-5. PubMed ID: 19461405
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
Pagano M; Sierra NM; Panebianco M; Rossi G; Gnoni R; Bisagni G; Boni C
Anticancer Res; 2014 Sep; 34(9):5105-10. PubMed ID: 25202099
[TBL] [Abstract][Full Text] [Related]
3. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Schirosi L; Nannini N; Nicoli D; Cavazza A; Valli R; Buti S; Garagnani L; Sartori G; Calabrese F; Marchetti A; Buttitta F; Felicioni L; Migaldi M; Rea F; Di Chiara F; Mengoli MC; Rossi G
Ann Oncol; 2012 Sep; 23(9):2409-2414. PubMed ID: 22357254
[TBL] [Abstract][Full Text] [Related]
4. Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation.
Dişel U; Oztuzcu S; Beşen AA; Karadeniz C; Köse F; Sümbül AT; Sezer A; Nursal GN; Abalı H; Ozyılkan O
Lung Cancer; 2011 Jan; 71(1):109-12. PubMed ID: 20970876
[TBL] [Abstract][Full Text] [Related]
5. Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.
Buti S; Donini M; Sergio P; Garagnani L; Schirosi L; Passalacqua R; Rossi G
J Clin Oncol; 2011 Nov; 29(33):e803-5. PubMed ID: 21969494
[No Abstract] [Full Text] [Related]
6. Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.
Neuhaus T; Luyken J
Target Oncol; 2012 Dec; 7(4):247-51. PubMed ID: 23090205
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
8. 18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma.
Siemerink EJ; Mulder NH; Brouwers AH; Hospers GA
Oncologist; 2008 Jun; 13(6):734-5; author reply 736-7. PubMed ID: 18586929
[No Abstract] [Full Text] [Related]
9. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
10. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
[TBL] [Abstract][Full Text] [Related]
11. Do thymic malignancies respond to target therapies?
Hu B; Rong H; Han Y; Li Q
Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):855-9. PubMed ID: 25754373
[TBL] [Abstract][Full Text] [Related]
12. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.
Wilhelm S; Carter C; Lynch M; Lowinger T; Dumas J; Smith RA; Schwartz B; Simantov R; Kelley S
Nat Rev Drug Discov; 2006 Oct; 5(10):835-44. PubMed ID: 17016424
[TBL] [Abstract][Full Text] [Related]
13. Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.
Force J; Rajan A; Dombi E; Steinberg SM; Giaccone G
J Thorac Oncol; 2011 Jul; 6(7):1267-73. PubMed ID: 21610525
[TBL] [Abstract][Full Text] [Related]
14. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report.
Li XF; Chen Q; Huang WX; Ye YB
Med Oncol; 2009; 26(2):157-60. PubMed ID: 18846437
[TBL] [Abstract][Full Text] [Related]
15. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.
Ströbel P; Hartmann M; Jakob A; Mikesch K; Brink I; Dirnhofer S; Marx A
N Engl J Med; 2004 Jun; 350(25):2625-6. PubMed ID: 15201427
[No Abstract] [Full Text] [Related]
16. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
LaRocca RV; Hicks MD; Mull L; Foreman B
J Gastrointest Cancer; 2007; 38(2-4):154-6. PubMed ID: 19089671
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.
Simonelli M; Zucali PA; Suter MB; Lorenzi E; Rubino L; Fatuzzo G; Alloisio M; Santoro A
Future Oncol; 2015; 11(8):1223-32. PubMed ID: 25832879
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
20. Absence of gene mutations in KIT-positive thymic epithelial tumors.
Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
